Longevity-linked gene variant tied to platelet immune changes
Human observations and laboratory tests found that carriers of the variant had platelets with more of a surface protein and stronger anti-inflammatory effects.
Limit: Platelet proteins and laboratory immune responses are surrogate measures, not health outcomes
Edited by Boris Djordjevic · AgingResearch.News
Researchers studied platelets, blood fragments that help clotting, from centenarians and people carrying a longevity-associated variant of the BPIFB4 gene. The study combined human observations with laboratory experiments.
Centenarians had a higher share of immature platelets carrying CD47, a surface protein. Variant carriers had higher CD47 levels on both immature and mature platelets. In laboratory tests, carriers’ platelets reduced activation of monocytes, a type of immune cell, and production of inflammatory signals through mechanisms dependent on CD47. In separate animal experiments, giving mice a manufactured version of the variant protein increased platelet CD47. Tests outside the mice also found reduced monocyte activation in response to an inflammatory stimulus.
Why it matters
The authors proposed using the variant protein to manage age-related inflammation and cardiovascular disease by reproducing some immune features associated with exceptional longevity.
Caveats
The human observations cannot establish cause and effect, and the laboratory findings do not establish health benefits in people. The abstract does not report participant numbers.
